Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Johnson & Johnson

< Previous 1 2 3 Next >
Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson Reports Q1 2025 Results
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson Reports Q4 and Full-Year 2024 Results
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
From Johnson & Johnson
Via Business Wire
Tickers ITCI JNJ
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson Reports Q3 2024 Results
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson to Participate in the Stifel 2024 Healthcare Conference
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson Completes Acquisition of V-Wave
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson to Acquire V-Wave
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson reports Q2 2024 results
From Johnson & Johnson
Via Business Wire
Tickers JNJ
Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26
From Johnson & Johnson
Via Business Wire
Tickers JNJ
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.